Insulet Corporation, under the ticker PODD, shows potential in the medical devices sector, focusing on innovative insulin delivery systems. The stock’s fundamentals reveal a balanced perspective, with room for growth in certain areas such as the discounted cash flow. Investors should consider both current and historical ratings alongside analyst sentiments for a comprehensive evaluation.
The current fundamentals suggest a moderate evaluation with strong points in return ratios, but challenges remain in valuation metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow (DCF) | 1 | |
| Return on Equity (ROE) | 5 | |
| Return on Assets (ROA) | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Comparison of current vs. past scores highlights consistent performance in key areas such as ROE and ROA.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-21 | 3 | 1 | 5 | 5 | 3 | 1 | 1 |
| N/A | 0 | 1 | 5 | 5 | 3 | 1 | 1 |
Analyst targets provide a consistent outlook with the current consensus aligning with the median price target.
| High | Low | Median | Consensus |
|---|---|---|---|
| $322 | $322 | $322 | $322 |
The analyst sentiment reflects a generally positive outlook, with a majority of analysts recommending a 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 28 | |
| Hold | 13 | |
| Sell | 2 | |
| Strong Sell | 0 |
Insulet Corporation presents a strong case in the healthcare market, with innovative solutions in the insulin delivery segment. While the company shows promising returns on equity and assets, valuation metrics remain an area for improvement. The analyst sentiment is predominantly positive, with a consensus towards buying, reflecting confidence in the company's future prospects. However, potential investors should consider market dynamics and financial strategies for debt management. Overall, the stock holds potential for long-term growth, especially with advancements in its product offerings.